The treatment landscape for patients with prostate cancer, especially individuals with advanced disease, has dramatically ...

Prostate cancer accounts for 3.8% of total cancer-related deaths worldwide. The combination of docetaxel and androgen deprivation therapy is useful in the management of the disease, but unfortunately, ...

Furthermore, docetaxel (the drug of choice for the ... BM: Brain metastasis; CRPC: Castration-resistant prostate cancer; CT: Computed tomography; NA: Not assessed; NMR: Nuclear magnetic resonance ...

On International Men's Day, the Clinical Trials Arena team investigates three therapies being investigated in prostate cancer ...

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate ...

Docetaxel plus prednisone as a first-line ... The identification of new drug resistance mechanisms and prostate cancer molecular subtypes based on genomic and proteomic analysis, as well as ...

ONCOLife proudly presents an exclusive interview with Dr. Iris Kuss, VP and Global Development Lead Oncology at Bayer. In ...

Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.

prostate cancer and non-small cell lung cancer either alone or with other medications. It belongs to taxane group. It stops the growth and spread of cancer cells. When should Docetaxel not be taken?

Analyses found lower cardiotoxicity from triplet mHSPC therapy involving darolutamide vs abiraterone/prednisone in addition to ADT and docetaxel. Triplet therapy ...